Effect of oxyprogesterone caproate, tamoxifen and their combination on the level of steroid hormone receptors in the tumor, and some parameters of the reproductive system in patients with endometrial cancer.
The results of preoperative use of oxyprogesterone caproate (OPC), Tamoxifen and their combination in 165 patients suffering from primary endometrial carcinoma are presented. It was shown that Tamoxifen was able to increase concentrations cytoplasmatic receptors to progesterone in the tumor. The incidence of specific hormonal pathomorphosis in the tissue of the tumor in patients who received a combination of OPC and Tamoxifen was significantly higher (80% of cases) as compared to the separate use of OPC (60%) or Tamoxifen (57%).
Vishnevsky
A S
AS
Petrov Research Institute of Oncology, Leningrad, USSR.
Shtofmakher
J A
JA
Bokhman
J V
JV
Tsyrlina
E V
EV
Bobrov
J F
JF
Chepick
O F
OF
Sofroniy
D F
DF
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003593:Cytoplasm / Q000378:metabolism; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000378:metabolism; D008875:Middle Aged; D011959:Receptors, Estradiol / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D014621:Vagina / Q000473:pathology
D006908:Hydroxyprogesterones; D011959:Receptors, Estradiol; D011980:Receptors, Progesterone; D013629:Tamoxifen; D000077713:17 alpha-Hydroxyprogesterone Caproate; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone